FORT WORTH, Texas, Feb. 1, 2017 /PRNewswire/ -- Galderma, a global leader focused on medical solutions in skin health, announced today that they have partnered with actress Ashley Benson to celebrate the national launch of Differin Gel. The product is the first and only FDA-approved, prescription-strength, retinoid acne treatment available OTC and the newest advancement in the OTC acne category in over 30 years.
Ashley will host a media event at the Nestlé Skin Health Investigation, Education, Longevity Development (SHIELD) Center in New York City on February 1, 2017 to officially launch the Differin collection.
“We are proud and honored to have Ashley supporting the launch of Differin Gel,” said Miles Harrison, President and General Manager of Galderma Laboratories, L.P. “As someone who is constantly in the spotlight and has dealt with acne as an adult, she knows firsthand how difficult it can be. She represents millions of adult acne sufferers who have tried every treatment on the market with no long-term results. That’s why we’re incredibly happy she is helping us celebrate Differin Gel, a product that will help break the cycle of adult acne frustrations.”
Pretty Little Liars star Ashley Benson has been open about her personal struggle with acne on social media, posting “zit” selfies that have gone viral across the internet. Having suffered from periodic breakouts throughout her adult life, Ashley is passionate about sharing her journey and the positive results she has had since using Differin Gel.
“Hectic travel schedules and long shoot days have taken a serious toll on my skin,” said Ashley. “That’s why I am so proud to be a part of the national launch of Differin. The retinoid gel is such a game-changer for acne sufferers like me.”
Acne affects more than 50 million people annually1 and only one-third (36%) seek the help of a healthcare provider2. However, 81% of adult sufferers agree they have never found a completely effective treatment3. As of January, Differin Gel will be available over the counter to help consumers effectively clear breakouts where they start, prevent lesions before they begin, and as a result, restore their skin’s texture and tone.
In addition to the Gel, Differin will be introducing a non-foaming, fragrance-free Balancing Cleanser and a gentle Balancing Moisturizer.
About Differin® Gel
Differin® Gel containing 0.1% adapalene is the first and only FDA-approved, prescription-strength, retinoid acne treatment available over the counter and the newest advancement in the OTC acne category in over 30 years. Differin® Gel is specially formulated for efficacy and tolerability. It is a full prescription-strength, once-a-day topical containing a retinoid, which is clinically proven to treat current and future breakouts. An innovation from Galderma R&D, the dermatologist-developed and tested Differin® Gel contains adapalene, a safe and effective retinoid, which doctors have prescribed to over 40 million people globally for more than 20 years4. According to the American Academy of Dermatology’s therapeutic treatment guidelines, topical retinoids are recommended as first-line therapy for all acne cases5.
Differin® Gel is clear, fragrance-free, oil-free and alcohol-free. Differin® Gel is applied once daily, directly to the full-face or other affected areas. It is approved for use by people 12 years and older with acne. For more information, please visit www.differin.com.
About Galderma
Galderma, Nestlé Skin Health’s medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.
Strategic brands in the U.S. include Epiduo® Gel, Epiduo® Forte Gel, Oracea® Capsules, Clobex® Spray, Mirvaso® Gel, MetroGel® Gel, Soolantra® Cream, Vectical® Cream, Tri-Luma® Cream, Cetaphil®, Differin® Gel OTC, Restylane®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Dysport® and Sculptra® Aesthetic.
For more information, please visit www.galdermausa.com and www.galderma.com.
About Nestlé Skin Health SHIELD
Nestlé Skin Health’s mission is to enhance quality of life by delivering science-based solutions for the health of skin, hair and nails. Nestlé Skin Health SHIELD (Skin Health Investigation, Education, Longevity Development) is a global network for innovation and education that gathers today’s most creative and visionary thinkers from diverse disciplines to generate, develop and incubate ideas to advance skin health and wellbeing. Ideas generated from SHIELD may result in new technologies, treatments, publications, white papers or educational approaches. For more information, please visit www.nestleskinhealth.com/shield.
Contact
Shannon Iwaniuk, Corporate Communications
Galderma Laboratories, L.P.
14501 N. Freeway, Fort Worth, TX 76177
Shannon.Iwaniuk@galderma.com
Alissa Katz, Account Supervisor
Lippe Taylor
215 Park Avenue South, New York, NY 10003
AKatz@LippeTaylor.com
References
1 Bickers DR, Lim HW Margolis D, Weinstock MA, Goodman C, Faulkner E Et Al. The Burden Of Skin Diseases: 2004 a joint project of the American Academy of Dermatology Association and The Society For Investigative Dermatology Journal of The American Academy of Dermatology 2006; 55:490-500.
2 Nielsen Research Survey of Acne Sufferers. 2015
3 The 2016 Gallup Study of the Market for Acne Products Among Young Adults, 18-40 Years of Age; Multi-sponsor Surveys, Inc. Q26/Q62; n=503
4 Data on file, Galderma Laboratories, L.P.
5 Treatment and management of acne.” American Academy of Dermatology. AAD.org, 6 May 2016. Web. 26 June 2016.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/differin-gel-acne-treatment-partners-with-actress-ashley-benson-to-end-adult-acne-frustrations-for-millions-of-sufferers-300399727.html
SOURCE Galderma
